Goblet cell depletion occurs in various forms of colitis, but its mechanism is unknown. We have investigated two linked hypotheses : (i) that bacterial peptides, such as formyl-methionyl-leucylphenylalanine (fMLP), interact with epithelial cells inducing the release of chemokines, including interleukin-8 (IL-8), which in turn leads to the recruitment of neutrophils which release mucin secretagogues ; (ii) that fMLP acts directly on epithelial cells to cause mucus secretion. Studies were performed to measure the effects of fMLP on the synthesis and secretion of IL-8 and mucus by the goblet cell differentiated colon cancer cell lines HT29-MTX (methotrexate-conditioned HT29 colonic adenocarcinoma cell line) and LS174T, and to assess the effects of neutrophilderived secretagogues on goblet cell secretion in these cell lines. fMLP (0.1 µM) increased the secretion of IL-8 by 105 % (P 0.0001) in HT29-MTX cells and by 401 % (P 0.0001) in LS174T cells. fMLP also increased the synthesis and secretion of mucins by these cell lines, with maximal effects of 65 % above control values for synthesis (P 0.01) and 73 % for secretion (P 0.01). A dose-related increase (up to 67 % ; P 0.01) in mucin secretion was demonstrated in HT29-MTX cells in response to incubation with supernatant from activated neutrophils. This effect was largely (83 % ; P 0.02) inhibited by ICI 200,355, a specific inhibitor of neutrophil elastase. In conclusion, the bacterial peptide fMLP and neutrophil elastase are both potent mucus secretagogues for colon epithelial cells. fMLP also elicits release of the potent neutrophil chemoattractant IL-8 from colon epithelial cells. These findings support the hypothesis that the mucosal inflammation and mucus depletion seen in ulcerative colitis could result from interaction between bacterial peptides and the mucosa.
INTRODUCTION
Enteric bacteria have a crucial role in the pathogenesis of colitis. In transgenic models of colitis, the phenotype is invariably exhibited only in the presence of enteric flora bowel disease that lack conventional pathogenicity genes [4] . It has been postulated previously by Broom et al. [5] that even non-pathogenic E. coli, when closely associated with the mucosa, would be stressed by the relatively oxygen-rich environment. This stress would activate production of the SOS-operon protein, the degradation and N-formylation of which results in the formation of N-formyl-methionyl-leucyl-phenylalanine (fMLP). If the colon epithelial cells were able to respond to fMLP, this would provide a possible mechanism for inflammation without a requirement for bacterial invasion or toxin production.
fMLP is present in the colonic lumen fluid at a concentration of approx. 0.1 µM [6] , and is the major chemotactic peptide produced by E. coli [7] . In experimental animals, colonic infusions of fMLP induce colitis [8, 9] . It is not clear from the literature whether human colon epithelial cells might be expected to respond to fMLP. One study failed to demonstrate expression of the specific fMLP receptor on colon epithelium [10] ; however, fMLP also interacts with the PepT1 transporter, which is expressed by colonic mucosal cell lines [11] and which becomes expressed by the human colon in disease states [12] .
One of the most striking features of inflammatory bowel disease is marked mucosal neutrophil infiltration, whereas the normal colonic mucosa is almost devoid of neutrophils. The chemotactic peptide interleukin-8 (IL-8) is of particular importance in the recruitment of neutrophils [13, 14] and has been shown to be secreted by various cell types, including colonic epithelial cells, monocytes, fibroblasts and endothelial cells [15] [16] [17] [18] [19] . Colonic epithelial cell lines secrete IL-8 in response to bacterial entry [20] , and the IL-8 concentration is increased in the colonic mucosa of patients with inflammatory bowel disease [21, 22] .
One of the protective mechanisms available to inflamed epithelial surfaces is increased mucus secretion. Rapid mucus secretion is stimulated by various secretagogues : acetylcholine, carbachol, pilocarpine, neuroendocrine mediators such as vasoactive intestinal polypeptide, neurotensin and neuromedin, PMA, forskolin, interleukin-1 and mustard oil [23] [24] [25] [26] [27] [28] [29] [30] [31] . Additional potential secretagogues are known to exist in inflamed mucosa ; these include a mast cell secretagogue in the colon [32] and neutrophil elastase in the respiratory epithelium [33] . ' Goblet cell depletion ' is a recognized feature in ulcerative colitis [34, 35] , infective colitis [36] , irradiation colitis [37] and many experimental models of colitis [38] , but typically does not occur extensively in Crohn's disease [39] . In experimental models of colitis induced by rectal instillation of acetic acid or dinitrochlorobenzene sensitization, Kaftan and Wright [40] noted an apparent increased loss of [$H]thymidine-labelled goblet cells compared with non-goblet cells, but commented that it was unlikely that there was selective drop-out of goblet cells from the mucosa. These workers speculated that the apparent goblet cell depletion might be due to goblet cells losing their characteristic phenotype, rather than the selective loss of goblet cells.
We propose linked hypotheses that bacterial Nformylated peptides, such as fMLP, might either (i) interact with epithelial cells inducing chemokine release (in particular IL-8), causing attraction and activation of neutrophils, which subsequently release secretagogues which stimulate mucus secretion, or (ii) interact directly with epithelial cells to cause mucus secretion. To investigate these hypotheses, we performed studies to measure the effects of fMLP on the secretion of IL-8 and mucus in gastrointestinal epithelial cell lines, and the effects of potential secretagogues on goblet cell secretion in these cell lines.
METHODS

Materials
The methotrexate-conditioned HT29 (HT29-MTX) cell line was a gift from Professor Alain Zweibaum (Unite de Recherches sur la Differenciation et la Neuroendocrinologie de cellules Digestive, INSERM U178, 94807 Villejuif Cedex, France). This cell line consists almost exclusively of goblet cell differentiated colonocytes [41] . The colonic adenocarcinoma cell line LS174T was obtained from the European Collection of Animal Cell Cultures (ECACC, Porton Down, U.K.). fMLP was purchased from Sigma (Poole, Dorset, U.K.).
The highly specific inhibitor of human neutrophil elastase, ICI 200,355 [4-(4-bromophenylsulphonylcarbamoyl-L-valyl-L-proline 1-(R,S)-(1-trifluoroacetyl-2-methylprolyl)amide], was supplied by Zeneca (Macclesfield, U.K.) [42] . The CAM17.1 monoclonal anti-(human mucin) antibody was donated by Dr Carol Makin (Imperial Cancer Research Fund, London, U.K.). Recombinant human tumour necrosis factor-α (TNF-α) was purchased from R&D Systems (Abingdon, Oxon., U.K.). Unless indicated otherwise, all other chemicals were obtained from Sigma.
Cell culture
Both cell lines were grown in plastic 25 cm# culture flasks (Costar, Cambridge, MA, U.S.A.) and maintained at 37 mC in a 5 %CO # \95 % air atmosphere in Dulbecco's modified Eagle's medium (DMEM) containing 2 mM glutamine and 100 units\ml penicillin\streptomycin (Gibco BRL Life Technologies Ltd, Paisley, U.K.), with 10 % (v\v) fetal calf serum for HT29-MTX cells and 15 % (v\v) fetal calf serum for LS174T cells. Cells were passaged at 70-80 % confluence (usually 5-6 days ; cell density " 10( cells\flask) and then were seeded to 24-well plates at a cell density of (1-2)i10% cells\well and cultured in 0.5 ml of medium\well. Cell monolayers were used in experiments 6-7 days after becoming confluent.
IL-8 release by colon cancer cell lines in reponse to fMLP
The two colon cancer cell lines were each treated with the chemotactic peptide fMLP dissolved in DMSO vehicle to final concentrations of between 1 nM and 10 µM for 48 h at 37 mC. The vehicle alone was used as a control. E. coli lipopolysaccharide and TNF-α at concentrations of 75 and 50 ng\ml respectively were used as positive controls for IL-8 release. Following incubation, the medium was collected, pooled with two washes of the cell monolayers (2i250 µl) with sterile serum-free medium and centrifuged at 400 g for 10 min. The cell monolayers were harvested by careful scraping into 500 µl of sterile PBS containing 0.1 % (w\v) thimerosal, followed by ultrasonication (8i15 s bursts at 25 % amplitude ; GEX 400 Ultrasonic Processor ; Sigma) and centrifugation for 10 min at 11 000 g in an Optima TLX-120 centrifuge (Beckman, Palo Alto, CA, U.S.A.). IL-8 was measured in both the cells and the cell-free medium using a solidphase sandwich ELISA with an antibody specific for IL-8 coated on to the microtitre wells (Cytoscreen4 IL-8 kit ; Biosource International, Camarillo, CA, U.S.A.). Standards of known IL-8 concentration in cell-lysis buffer and cell-free culture medium were assayed in triplicate. The within-assay coefficient of variation for the standards was 4.5 % (n l 6), and the between-assay coefficient of variation was 6.2 % (n l 4). The lower detection limit of the ELISA was 7 pg\ml.
Mucin synthesis and secretion in response to fMLP
HT29-MTX cells were cultured in medium containing 2 µCi of N-acetyl-D-[1-$H]glucosamine (5.2 Ci\mmol ;
Amersham-Pharmacia Biotech, Little Chalfont, Bucks., U.K.). fMLP was added to the cell monolayers to a final concentration of 1 nM-10 µM for 48 h at 37 mC. Vehicle (DMSO) alone was used as a control. Following culture, mucin secreted into the medium was harvested and pooled with two further 250 µl cell monolayer washes using PBS, pH 7.4. Cellular mucins were harvested by careful scraping of the cells into 500 µl of PBS, followed by ultrasonication and centrifugation for 10 min at 11 000 g in an Optima TLX-120 centrifuge. Mucins were purified by gel filtration on mini columns packed with Sepharose CL-2B (Pharmacia, Uppsala, Sweden) and eluted with 500 µl aliquots of PBS, pH 7.4, as described by Finnie et al. [43] . Fractions were monitored by ELISA using a mouse anti-(human mucin) monoclonal antibody, CAM 17.1, as described by Parker et al. [44] . The void volume fractions, containing the high-molecular-mass mucins, were each mixed with 6 ml of Optiphase Safe scintillant (Wallac, Milton Keynes, U.K.), and β-radiation 
Measurement of cellular DNA
DNA was measured by indirect fluorography carried out using the method of Labarca and Paigen [45] .
Response to secretagogues of goblet cell differentiated HT29-MTX cells
Mucins were radiolabelled by the addition of 1 µCi\well of D-[6-$H]glucosamine hydrochloride (15-35 Ci\ mmol ; Amersham-Pharmacia Biotech) to the culture medium of HT29-MTX cells, as described above. Medium was removed, cells were washed with sterile PBS and fresh DMEM was added. To assess the effect of activated neutrophil supernatant (see below), doublechamber 6.5 mm (0.4 µm membrane) Transwell2 culture plates (Costar, High Wycombe, U.K.) were used to allow application of the secretagogues to the basolateral aspect of the goblet cell differentiated HT29-MTX cells. Further experiments were performed in which the activated neutrophil supernatant was added in the presence of the specific inhibitor of neutrophil elastase, ICI 200,355, at 1 µM [42] . At 4 h the culture medium from the upper well was removed and mucin radioactivity was measured by β-radiation counting after gel filtration, as described above.
Preparation of activated neutrophil supernatant
Heparinized blood (30 ml) from a healthy subject was layered in 3.5 ml aliquots on to 3 ml of MonoPoly resolving medium (ICN Pharmaceuticals, Basingstoke, U.K.) and centrifuged at 400 g for 30 min at room temperature, and the neutrophil-rich layer was collected. This layer was then washed with calcium-and magnesium-free Hanks balanced salt solution (Gibco) and centrifuged at 250 g for 10 min, the supernatant was discarded and the cells were resuspended in DMEM. This technique achieved a final concentration of neutrophils of 65i10'\ml. Neutrophils were stimulated by incubation with 1 µM PMA for 60 min. The supernatant was collected and assessed as a secretagogue as described above.
Statistical analysis
Sample groups were analysed using one-way ANOVA followed by pairwise comparisons of the means (Arcus Pro-Stat2 ; Medical Computing, Aughton, Lancs., U.K.). Differences were considered significant when 2P 0.05.
RESULTS fMLP stimulates IL-8 release by colonocytes
Treatment of HT29-MTX colonocytes with fMLP significantly enhanced the release of IL-8, in a dosedependent manner, above the basal level of 201p 12.2 pg\mg of cellular protein (meanpS.E.M. ; n l 8) ( Figure 1A ). The maximal effect was seen at a concentration of 0.1 µM (346p14.3 pg of IL-8\mg) (P 0.0001, ANOVA ; n l 8). A much larger response was seen with LS174T colonocytes, with 0.1 µM fMLP increasing IL-8 release to 671p19.2 pg\mg of cellular protein compared with basal levels of 237p11.4 pg\mg (P 0.0001, ANOVA ; n l 6).
Treatment of HT29-MTX cells with fMLP also increased intracellular levels of IL-8 significantly, to a peak of 632p17.3 pg of IL-8\mg of cellular protein at a concentration of 1 µM fMLP, compared with 212p 20.1 pg\mg in control cells (P 0.01, ANOVA ; n l 8) ( Figure 1B) . A similar response was observed in LS174T colonocytes, although the peak response occurred at a concentration of 0.1 µM FMLP (P 0.01, ANOVA ; n l 6). Similarly, total IL-8 was increased in both cell lines ( Figure 1C ).
Significant release of IL-8 was also seen from both cell lines in response to 48 h of treatment with 75 ng\ml E. coli lipopolysaccharide ( Figure 1D ) or 50 ng\ml TNF-α ( 2 ng of IL-8\ml for both cell lines ; results not shown). fMLP, lipopolysaccharide and TNF-α had no significant effects on cellular DNA levels over 48 h at any concentration tested (results not shown). fMLP at 100 µM did cause a significant fall in DNA content (to 57 % of control), and data obtained with that and higher concentrations of fMLP were therefore ignored. The effect of 75 ng/ml E. coli lipopolysaccharide on IL-8 release from the cell lines is also shown (D). Values are meanspS.E.M. (HT29-MTX cells, n l 8 ; LS174T cells, n l 6). Significant differences from vehicle (DMSO) : ****P 0.0001, ***P 0.001, **P 0.01 (ANOVA). Mechanisms for goblet cell depletion
Figure 2 fMLP increases mucin secretion from (A) and total mucin synthesis in (B) HT29-MTX cells
The incorporation of N-[ 3 H]acetylglucosamine into mucin was measured (d.p.m./µg of cellular DNA). Values are meanspS.E.M., and are expressed as percentages of control (DMSO vehicle). Significant differences from control : ***P 0.001, **P 0.01, *P 0.05 (n l 8 ; ANOVA). 
Neutrophil granule products stimulate mucus secretion by goblet cell differentiated HT29-MTX cells
The activated neutrophil supernatant caused a doserelated increase in mucus secretion from HT29-MTX cells when applied to the basolateral surface. A 67 % increase in radiolabelled mucin secretion was observed in cells stimulated with 200 µl of stimulated neutrophil supernatant (P 0.01, ANOVA ; n l 3). This effect was inhibited by 83 % by the addition of a specific inhibitor of human neutrophil elastase, ICI 200,355 (P l 0.016, ANOVA ; n l 3) (Figure 3 ), suggesting that elastase from PMA-stimulated neutrophils is a major stimulant of mucin secretion in HT29-MTX cells.
DISCUSSION
These studies show that fMLP at a concentration similar to that in the normal human colonic lumen causes secretion of IL-8 and mucin by colon epithelial cell lines. The ' bell-shaped ' dose-response curve seen for fMLPinduced mucin secretion, and to a lesser extent for IL-8 release, is typical of cellular responses to this cytokine [46] . Human neutrophil elastase is shown to be a potent stimulus to mucin secretion in goblet cell differentiated HT29-MTX colon cancer cells, and seems likely to be an important mucus secretagogue in the inflamed colon. These data support the hypothesis that the mucus secretion and goblet cell depletion that occurs in colitis may be mediated by the interaction between bacterial peptides and the mucosa, either via a direct effect or via an indirect effect involving neutrophil recruitment and stimulation. Previous studies have shown that IL-8 itself does not stimulate mucus secretion by cultured gastric epithelial cells [47] .
Conflicting evidence exists regarding the expression of fMLP receptors on epithelial cells [10, 48] . Anton et al. [10] failed to demonstrate classical fMLP receptors in 10 epithelial cell lines examined, and in tissue sections it appeared that fMLP binding was subepithelial only. However, the epithelial protein PepT1, which is expressed by the colon cancer cell line Caco2 [49] and also by the human colon in disease states [12] , has been shown to transport fMLP in Caco2-BBE cells [11] . It may be that this and other non-classical fMLP receptors [50] are involved in the uptake of N-formyl peptides. Our data show that fMLP has a direct effect on mucin secretion in HT29-MTX cells. At the time that the present studies were carried out, PepT1 antibody [49] was not available to check for expression of this protein in HT29-MTX and LS174T cells.
Neutrophil elastase has not been demonstrated previously to be a secretagogue in the human colon, but is known to be a potent secretagogue in the respiratory epithelium [42, [51] [52] [53] . Bronchiectasis is characterized by Figure 4 Hypothesis for the interaction between bacterial peptides, neutrophils and goblet cells chronic excess sputum production and increased sputum elastase, and the secretory effect of bronchiectatic sputum on cultured bovine tracheal cells has been shown to be inhibited by 70 % by the specific neutrophil elastase inhibitor ICI 200,355 [53] . This inhibitor had no effect on baseline mucin secretion, and was shown previously to have no effect on the secretory response to other neutrophil products, such as cathepsin G, in cultured bovine tracheal cells [51] . The residual secretory effect of the neutrophil supernatant in the presence of ICI 200,355 may well be due to the presence of PMA, which is itself a mucus secretagogue acting via protein kinase C activation [54] .
Elastase that is bound to the neutrophil membrane is probably more bioactive within tissue, since free elastase is inhibited rapidly by extracellular inhibitors [55] . This would imply that neutrophils would need to be in close apposition to goblet cells, as in a crypt abscess, in order to stimulate mucus secretion, and this fits well with the histological association between crypt abscess formation and goblet depletion seen in colitis. fMLP has been shown to stimulate markedly the expression of membrane-bound neutrophil elastase [56] . Further studies are needed to ascertain whether elastase interacts with a specific receptor on the epithelial cell membrane.
In Crohn's disease, goblet cell depletion is much less conspicuous, despite extensive inflammation [39] . We suggest that this might be due to the relative dysfunction of neutrophil polymorphs reported in Crohn's disease [57] [58] [59] , which is also in keeping with the Crohn's-like intestinal lesions seen in association with severe phagocytic dysfunction disorders such as chronic granulomatous disease [60] and glycogen storage disease type 1b [61] . We have speculated that neutrophil dysfunction in Crohn's disease might be particularly marked within the mucosa as a result of the known inhibitory effect on the release of neutrophil myeloperoxidase [62] of microbial cell wall oligomannan, which is the epitope for the antiSaccharomyces cerevisiae antibody (ASCA). If this hypothesis is correct, it would imply that the indirect effect of bacterial peptides such as fMLP on mucus secretion mediated via neutrophil recruitment and activation is likely to be quantitatively more important than the direct effect of fMLP on mucus secretion.
We propose a model ( Figure 4 ) whereby nonpathogenic bacteria adjacent to colonic mucosa, and hence under oxidative stress, release bacterial peptides such as fMLP that induce cytokine release from epithelial cells. This will cause recruitment and activation of neutrophils, and release of mediators such as elastase which stimulate mucus secretion.
